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Introduction: Croatia has introduced a number of reforms to contain pharmaceutical expenditure 
whilst increasing access to new medicines. These include new regulations and new ordinances in 
2013 including the pricing of new medicines and lowering the price of generics. Aims: Describe 
changes in the 2013 ordinance for new and established medicines in Croatia and the potential 
savings to provide future guidance. Methods: Descriptive review of the new ordinances for pricing 
and reimbursement of pharmaceuticals and calculations of potential savings from the various 
initiatives.  Results: There were changes in the ordinance for the pricing of new medicines in Croatia 
including the order of reference priced countries. There were also changes in the pricing of biosimilars 
as well as comparator levels with other countries. Projections show that with the new ordinance, 
ambulatory care expenditure for the 54 product groups (internal reference price system) will be 
reduced by 9.64% (318.4 million kunas) and prices of new medicines lowered by 8 to 10% following 
changes in the order of referenced price countries. Conclusion: This paper demonstrates that 
changes in the reference pricing system can lead to considerable differences in overall reimbursed 
expenditure. In addition, European countries with smaller populations can be active with introducing a 
variety of measures to keep pharmaceutical expenditure under control whilst increasing access to 
new medicines. Further reforms will be needed to improve the quality of prescribing. It is also likely 




Rising pharmaceutical expenditure is causing concern among countries, with expenditure rising by 
more than 50% in real terms during the past decade among OECD countries (1, 2). These concerns 
have resulted in multiple reforms and initiatives across Europe, which includes regulations regarding 
prices, reimbursement and utilisation of medicines (2, 3). Initiatives for established medicines include 
measures to obtain low prices for generics as well as encourage their prescribing (3-9). This includes 
both internal reference pricing systems (IRP) and external reference pricing (ERP) (9-13), with 
internal reference pricing currently utilised among 20 or more EU Member States and ERP among 24 
EU Member States (9, 12). Croatia is no different and has introduced a number of reforms in recent 
years to reduce debt levels, add new medicines to the reimbursement list and improve the quality of 
care (14-17). Measures include restricting medicines to second line, with follow-up by physicians 
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working for the Croatian Health Insurance Fund (CHIF) if abuse is suspected (18), as well as strict 
control of pharmaceutical company activities, with adherence enhanced through financial penalties 
(14, 15). In addition, regulations for lowering the prices of successive generics for a given molecule 
(14, 18). 
 
However, there is a continual need to conserve resources, as well as a continuing need to encourage 
the reimbursement of new valued medicines, given the level of unmet need, ageing populations and 
continued high unemployment affecting CHIF revenues (23,24). This led to the development of a new 
ordinance for the pricing of both new and established medicines including biosimilars. The old 
ordinance was published in the Official Gazette 155/2009, and its amendment published in the Official 
Gazette 22/2010, while the new ordinance was published in the Official Gazette 83/2013 and its 
amendment in the Official Gazette 12/2014 and Official Gazette 69/2014 (19-24). There is a 
recognised need to evaluate the influence of the new ordinance on potential savings, and use the 
findings to plan further pertinent measures. 
 
The Ordinance establishing the criteria for the inclusion of medicinal products onto the basic and 
supplementary Reimbursement Lists of the Croatian Health Insurance Fund (CHIF) has been enacted 
since 2013 (Official Gazette 83/2013) (20). The decision on accepting or rejecting new medicines for 
reimbursement is undertaken by the Committee for Drugs and Medicinal Products within the 
Administrative Council of the CHIF following a recommendation by the Commission for Drugs, which 
consists of 13 members who are all experts in their specific disease area.  
 
Key criteria for assessing the value of new medicines in Croatia, and their potential prices, include 
improved outcomes versus current standards including improved quality-of-life and/ or reduced 
adverse effects, more µXVHU-IULHQGO\¶IRUPXODWLRQVLPSURYLQJFRPSOLDQFHDVZHOODVLPSURYHGRYHUDOO
efficiency (14, 15). In addition, whether this is a new medicine where no treatment has previously 
existed; alternatively, a replacement treatment. There is also the potential for price reductions or 
price: volume agreements, including pay-backs or cross-product agreements, for new active 
substances with budget impact analyses requested for new medicines based on best practice and 
defined by the ordinance (14, 15, 17, 20). 
 
The prices of established as well as new medicines are regulated by Ordinances including biosimilars, 
vaccines and small molecules (19, 20). The ordinances also describe the procedure of calculating 
annual drug pricing (external reference pricing - ERP) as well as the method for setting reference 
prices of medicines and reference price systems (internal reference pricing ± IRP). ERP is a process 
in which the prices of medicines are compared with prices of medicines in comparable countries 
(Example contained in Table 3). IRP is based on the Anatomical Therapeutic Chemical (ATC) 
classification. This can be at ATC Level III (pharmacologic group, e.g. lipid modifying agents), Level 
IV (pharmacologic class e.g. HMG CoA reductase inhibitors) or Level V (individual molecule) (14, 17, 
25). IRP is a process in which CHIF established the reference prices of medicines, which are the 
reimbursed prices (Example in Table 4). CHIF covers the reference price, with patients covering any 
additional costs themselves for a more expensive product out-of-pocket.   
 
The reimbursed price on the two lists (basic and supplementary) is the ex-factory price combined with 
wholesale margins and other taxes up to 8.5%, which is wholesale price (WP) and tax (VAT) at 5%, 
as well as a pharmacy mark-up (fee) which is constant per package of medicines. Prices for non-
reimbursed medicines including OTC medicines are typically determined by market demand. Prices 
include WP, taxes (5% and 25%) and pharmaceutical margins (up to 35%). 
 
The Ordinances conform to the Directives of the European Commission regarding the pricing of 
medicines. According to these directives, each country determines the price of their medicines on the 
basis of a self-selected model, which must be clear and transparent, and must be implemented within 
set deadlines and in compliance with the directives (26).  The basic list of drugs, which are fully 
reimbursed, and the supplementary list of drugs, with CHIF covering the reimbursed part with the 
patient covering the remainder, are the final results of the current procedures in 2013 (27, 28). The 
basic list also includes expensive medicines that are funded out of different budgets. Drug lists are 





In Croatia, the share of public expenditures for health care is currently 6.6% of GDP (30, 31), with 
14.6% spent on pharmaceuticals in 2012 (31). This is down from 17% in 2007 (31). The various 
reforms in recent years have resulted in similar financial expenditure on prescription medicines in 
2012 compared with 2008, i.e. 3.303 billion kunas in 2012 (Euro 433million) versus 3.392 billion 
kunas (Euro 445million) in 2008. In addition between 2009 and 2011, 85 new medicines were added 
to the reimbursement list (30). Overall, 3044 packages of medicines were included in the basic drug 
list in 2012 and 390 drugs on supplementary list. This compares with 2047 packages of medicines in 
the basic list and 262 in the supplementary list in 2008.  
 
Consequently, the principal objectives of this paper are firstly to report on the new ordinances 
including changes in the reference price systems and compare these with the previous the previous 
ordinances. Secondly, compare potential savings from the changes in the reference price system 
(internal reference pricing ± IRP) at ATC Level III to V (current system) to just ATC Level V for 
comparative purposes among the 54 current reference price groups as a result of the recent reforms. 
Finally, suggest additional measures for consideration by CHIF in the future as CHIF strives to 
continue to provide comprehensive and equitable healthcare. 
 
We are not aware of many publications that have assessed the impact of changes to their external 
and internal reference pricing systems, although authors have calculated potential savings through 
converging prices to the average (12).  Consequently, we hope the findings and their implications will 
be of interest to the authorities in Croatia as well as other European countries that use reference 
pricing systems since we are aware there are some concerns with reference pricing initiatives (10, 
17). We will discuss these in the context of the findings in Croatia to stimulate further debate in this 




This includes a narrative review of the reforms comparing the old ordinances (2009) with the new 
ordinances (2013) among the co-authors (principally LSB), including the regulations surrounding: 
a) Placing new medicines on the list either as replacements for existing established medicines or 
entirely new treatments where none have existed before. This will be compared and contrasted with 
the old ordinance.  
b) Placing new generic medicines onto the drug lists, as well as comparing the old and new 
ordinances.  
c) The model for calculating the external reference pricing (ERP) for medicines and the implications 
(Example in Table 3) 
d) Internal pricing using a reference price system. We will describe the model of the internal reference 
price system (IRP) as well as the projected potential savings based on expenditure of medicines in 
the various reference price groups in 2012 (Example in Table 4)  
 
For external reference pricing, this included comparing potential savings with old and new ordinances. 
 
The calculation of potential savings from the changes in the internal reference pricing system (IRP) for 




Box 1 ± Calculations for potential savings from IRP among the 54 product groups as a result of the 
new ordinance 
 
a) Documenting the price of the drug unit (ATC Level V) by International non-proprietary name (INN), 
producer, trade name, formulation (including the number of capsules, tablets and other formulations 
as well as their strength) in 2012  
b) Documenting the reference prices in 2012 for each drug unit and each package in each of the 
reference classes based on the revised rules from the new ordinance (for unit price and price of 
package). This is based on the medicine with the lowest price within the referenced price group the 
previous year with a market share of at least 5% 
c) Deducting (a) from (b) to define potential savings per package 
d) Documenting total expenditure for each of the products in the 54 reference groups (ATC Level III to 
V) in 2011 
e) Multiplying the savings per package in 2012 by the 2011 consumption data to derive the overall 
projected expenditure for each package (c x d)  
f) Deriving the potential savings for each product group among the 54 reference groups (based on the 
presumption of similar expenditure in 2012 to 2011) 
f) Adding together all projected savings from (f) to derive potential savings from all 54 reference price 
product groups 
 
The potential savings arising from all the changes in the ordinances will also be calculated to provide 
a basis for any pertinent additional future reforms.  The analytic methods applied in the various 
situations are descriptive epidemiological methods, primarily involving a comparative analysis of 
pricing models of medicines under the old and new ordinances.  
 
The quality of the date is assured by regular auditing of the CHIF database. 
 
Suggestions for potential additional measures that CHIF could consider will be based on the 




This will be divided into four sections starting with placing new medicines placed onto the reimbursed 
list including new generics. 
 
A) Pricing of new medicines or new treatments including new generics 
 
The principal difference between the old and new ordinances is the pricing of biosimilars as well as 
new hospital medicines (Table 1). Hospital medicines are now included where there is an added 
health benefit compared with existing standards as there have been problems with their pricing in the 
past in the implementation and finalization proceedings. The list price in the new ordinance for new 
active substances demonstrating additional health benefit versus existing standards is now increased 
to 100% of their calculated prices, up from 90% of the comparable medicine. There is a 10% patient 
co-payment for ambulatory care medicines but not hospital medicines (Table 1).  
 
Table 1 - Model for placing new medicines on the drug list according to the old and new ordinances 
(16) 
 
Prices of new drugs on the lists Old ordinance New ordinance
New active substance (% of ACP)* 100 100
New active substance (% of price of comparable drug) 90 100 (90 reimburced)
New active substance, hospital drug (% of price of comparable drug) 100
Generic drug (% of price of previous drug) 70 70
Biosimilar (% of price of previous drug) 85
Generic drug (% of price of previous drug) 90 90
Generic drug (% of price of previous drug) 90 90





For new medicines or new active treatments where no treatment has existed before for the particular 
disease, the price is calculated based on external reference pricing (Table 2) as well as a % of the 
Average Comparable Price (ACP) (Table 1), based on prices of similar treatments in comparable 
countries (Table 2). 
 
It is envisaged the order of the countries used for external reference pricing (Table 2), alongside 
changes from the factors relating to retail versus wholesale prices, will affect subsequent reimbursed 
prices for new medicines in Croatia. This is because the average price of the package of medicines in 
comparable countries (without tax and margins) is translated into the unit price (in kunas) for that 
country and then into the price of the package of the drug that will be available in Croatia. After the 
translation, the ACP of the drug is calculated. The ACP is calculated as the average price of the same 
drug (same generic name, and the same or similar form and packaging) in the three chosen countries 
starting with Italy, Slovenia, and the Czech Republic, according to the new order established by the 
ordinance (Table 2). In cases where there is no comparative price for the new medicine in one 
country, then the average price of the medicine from the next country in the list of chosen countries is 
included and so on (Table 2) 
 
As seen in Table 1, the price calculations for the first and subsequent generics for small molecules 
are similar between the old and new ordinances. The main difference is that biosimilars are now 
included to address this anomaly, with the price of the first biosimilar at 85% of the originator price. 
The inclusion of biosimilars should accelerate savings as more biosimilars are launched for existing 
molecules and more biologicals lose their patents given the current high prices for biological 
medicines (32-38).  
 
B) Pricing of medicines under external reference pricing 
 
The principal differences in the ordinance for the external reference pricing (ERP) of existing 
medicines and new medicines where no medicine has existed before is the order of the reference 
price countries for calculating external reference prices (Table 2).  
 
ERP of established medicines is carried out once a year to make sure that the prices of established 
medicines in Croatia are not higher than the chosen European countries. ERP for established 
medicines used to take place the first Monday in February each year (20), but will now take place on 
the first Monday in March  (21). If the price of the medicine in Croatia is found to be higher than the 
ACP price, its price is subsequently reduced to the level of the ACP.  
 
x The sources for external pricing data are similar, i.e. official data from the countries included in 
the ordinance; however, there is now greater reliance on web-sources than publications (Table 2).  
Data sources include: Old ordinance: Italy - Informatore Farmaceutico; France ± Vidal; Slovenia ± 
Register; Spain  - Catalogo de Medicamentos; Czech Republic - www.vzp.cz  
x New: ordinance: Italy ± www.Codifa.it; Slovenia ± http://www.jazmp.si; Czech Republic - 
http://www.sukl.cz/; Spain ± µ&DWDORJRGH0HGLFDPHQWRV¶- latest electronic version, France ± 
µ9LGDO([SHUW¶ODVWHOHFWURQLFYHUVLRQ2WKHUFKDQJHVLQFOXGHgreater interaction with the legal 
persons and their representatives in each country who are involved in the registration and/ or 
pricing of medicines during the reference pricing process 
 
There have also been changes to some of the factors for the re-calculation from retail to wholesale 
prices to remove taxes and margins from the included countries and to enable comparisons based on 
WPs. The presented factors for the recalculation of the reference prices for the comparable countries, 




Table 2 ± External price regulations (17, 20) 
 
Description: Old ordinance New ordinance
Participants legal persons legal persons / their representatives
Prices of products (drugs) wholesale prices wholesale prices
Wholesale margins up to the 8,5% up to the 8,5%
Countries (for comparation of prices) Italy / France / Slovenia / Spain / Czech Italy / Slovenia / Czech / Spain / France
Factors of recalculation of RP* to WP** ITA 0.685 / FR - list  / SLO - WP / ES 0.693 / CZ 0,84 ITA 0.685 / SLO - WP / CZ 0.86 / ES 0.721 / FR - list  
Sources of prices web-sources or publications web-sources or publications
Level of comparation (% of ACP)***
Original products (with patent protection) 90 100
Original products (without patent protection) 65 100
Generic drugs 65 100
*RP - retail price
**WP - wholesale price




Under the new ordinance, prices remain at 100% of the average comparative price (ACP) of the 
medicine under the various regulations for new and established medicines including generics and 
biosimilars (Tables 1 and 2). Consequently, the calculation of the prices of both new and established 
medicines under the new ordinance appears applicable and acceptable to all key stakeholder groups. 
This was not the case with the old ordinance, especially if Croatia was a reference price country, as 
under the old ordinance prices were reduced by 10% and 35% of the average comparative price 
(ACP), i.e. prices were at  90% if patent protected and 65% if no patent protection of the ACP (Table 
2). Having said this, the order of countries for external reference pricing has changed potentially 
impacting on prices in Croatia along with changes in the factors involved (Table 2). In addition, the 
wording of the ordinances has changed (Table 2). 100% under the new ordinance for both originator 
and generic products enables fair market competition based on ACPs.  
 
Table 3 provides an example of the impact of the change in the ERP policy for omeprazole, with the 
change in the factors for calculating ACPs based on the change in factors from retail to wholesale 




Table 3 ± Example of external reference pricing for established medicines (omeprazole) based on the 
new ordinance for calculating ACPs (2013) 
 
DRUG PRICES OF DRUGS (EUR / CZK) PRICES OF DRUGS (KUNA) EXTERNAL PRICING






for package for drug unit Averige 
price for 
drug unit
1 2 3 4 5 6 7 8 9 10 11 12




0,00 0,00 0,00 0,00 0,00
Slovenia A02BC01 omeprasole ULTOP caps. 28x40 mg 14,14 107,21 3,83
A02BC01 omeprasole ULTOP caps. 28x40 mg 47,91 363,25 12,97
A02BC01 omeprasole ORTANOL caps. 28x40 mg 14,14 107,21 3,83
A02BC01 omeprasole ULZOL caps. 28x40 mg 10,71 81,20 2,90
0,00 0,00 5,88 caps. 28x40 m 164,64
Chezch A02BC01 omeprasole LOSEPRAZOL caps. 28x40 mg 580,97 499,63 147,86 5,28
A02BC01 omeprasole ORTANOL caps. 28x40 mg 563,96 485,01 143,53 5,13
0,00 0,00 0,00
0,00 0,00 0,00 5,20 caps. 28x40 m 145,60
Spain A02BC01 omeprasole BELMAZOL caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole EMEPROTON caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL ABDRUG caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL EDIGEN caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL ACTAVIS caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL NUPRAL caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL STADA caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL BEXAL caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL CINFA caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL CUVEF caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL DAVUR caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL KERN PHARMA caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL KORHISPANA caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL LAREQ caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL MABO caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL PENSA caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL RATIOPHARM caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL RIMAFAR caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL SANDOZ caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL SUMOL caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL PLACASOD caps. 28x40 mg 5,90 4,25 32,25 1,15
A02BC01 omeprasole OMEPRAZOL RIMAZOL caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL STADA caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL TARBIS FARMA caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL TEVAGEN caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL VIR caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole PEPTICUM caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole ULCERAL caps. 28x40 mg 4,64 3,35 25,36 0,91
A02BC01 omeprasole OMEPRAZOL ULCOMETION caps. 28x40 mg 4,64 3,35 25,36 0,91
0,00 0,00 0,91 caps. 28x40 m 25,48




0,00 0,00 0,00 0,00
AVERIGE COMPARABLE PRICE 111,91
1 EUR = 7,581946 kn










C) Internal reference pricing system  
 
The internal reference pricing system (IRP) has been introduced since it can happen on the 
reimbursed list that there are the same medicines with different prices. This is because new 
medicines can be placed on the list which contain the same INN, same dosage and packaging but 
with different prices due for instance to successive generics necessarily being priced 10% lower than 
the previous one for reimbursement (Table 1). Similarly, new single-sourced products (ATC Level III 
to V) can be placed on the reimbursement list at potentially lower prices. Similar to ERP, internal 
reference pricing takes place once a year once ERP has been performed. If the prices of the same 
medicine differ, their prices are subsequently reduced to the level of the reference price or lower. 
 
Prices of the originators are subsequently subject to internal reference pricing based on the lowest 
priced molecule in the class (ATC Level III to V) with a market share of 5% or more of the total market 
by volume. Should the authorization holder not accept the proposed price, i.e. want to keep the old 
price, the medicine is placed of the supplementary list with CHIF paying the reference price with 
patients covering any additional price themselves out-of-pocket.  
 
To illustrate this, a comparison has been performed (Table 4) building on the methodology described 
in Box 1. Reference prices are determined in relation to the unit price of the drug, or at the price of the 
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package for the drug, or the amount of active compound in a unit form of the medicine based on 
similar  defined daily doses (DDDs) (25). We are aware the WHO does not recommend the use of 
DDDs to compare prices of medicines. However, we are not aware of another appropriate comparator 
for determining (comparison) of prices especially if dosage forms and pack sizes vary. Determining 
reference prices of medicines by ATC Level III to V helps ensure similar prices are paid for the same 
molecule as well as for medicines that have the same or similar therapeutic effect. The reference 
price of a medicine requiring a prescription is determined by searching for the medicine with the 
lowest price within the pertinent reference group which in the previous year had a market share of at 
least 5% (14). We are also aware the reimbursement list may contain medicines that have not 
achieved a market share of 5%; however, their price cannot be used as reference price.  
 
The reference groups (currently 54 groups) for internal reference pricing (IRP) are determined by the 
Committee for Medicinal Products of the Ministry of Health. If the marketing authorization holder for 
the medicine, or its authorized representative, accepts the proposed reference price, their medicines 
will be placed on the basic list of drugs. As mentioned, if the authorization holder (originator or 
branded generic) rejects the proposed reference price, or keeps the old price, the medicine is placed 
on the supplementary list of medicines and the CHIF just pays the reference price for the particular 
medicine. Any difference in the price is subsequently paid by the patient out-of-pocket. The 
authorization holder (legal persons and their representatives) may also propose a price of their 
medicine which is lower than the current reference price to enhance its market share. 
 
Table 4 provides an example of the model for the internal reference price system (ATC level III to V) 
for the proton pump inhibitors (PPIs) in 2012.  
 
Table 4 ± Internal reference price system for the proton pump inhibitors (PPIs) -ATC levels III to V 
(2012) 
 
















A02BC01 103 omeprazole Ulzol caps. 28x10 mg 1,75 48,96 1,47 41,15
A02BC01 115 omeprazole Ortalox caps. 14x10 mg 2,24 31,36 1,47 20,57
A02BC01 116 omeprazole Ortalox caps. 28x10 mg 2,24 62,72 1,47 41,15
A02BC01 124 omeprazole Ortanol S caps. 28x10 mg 1,75 48,96 1,47 41,15
A02BC01 132 omeprazole Ultop S caps. 28x10 mg 2,24 62,72 1,47 41,15
A02BC02 101 pantoprazole Zipantola* tbl. 28x20 mg 1,47 41,15 1,47 41,15
A02BC02 111 pantoprazole Zoltex tbl. 28x20 mg 2,24 62,72 1,47 41,15
A02BC02 115 pantoprazole Apazol tbl. 28x20 mg 2,24 62,72 1,47 41,15
A02BC02 121 pantoprazole Acipan tbl. 28x20 mg 1,63 45,60 1,47 41,15
A02BC02 131 pantoprazole Nolpaza 20mg tbl. 28x20 mg 1,63 45,60 1,47 41,15
A02BC02 133 pantoprazole Nolpaza 20mg tbl. 30x20 mg 1,63 48,86 1,47 44,09
A02BC02 164 pantoprazole Controloc tbl. 28x20 mg 2,24 62,72 1,47 41,15
A02BC03 101 lanzoprazole Lansoprazol Pliva caps. 28x15mg 2,12 59,24 1,47 41,15
A02BC03 111 lanzoprazole Larona caps. 28x15 mg 2,24 62,72 1,47 41,15
A02BC03 121 lanzoprazole Lazol caps. 28x15 mg 2,24 62,72 1,47 41,15
A02BC03 132 lanzoprazole Lanzul S caps. 28x15 mg 2,24 62,72 1,47 41,15
A02BC02 126 pantoprazole Zoprax 20 mg tbl. 28x20 mg 1,81 50,81 1,47 41,15
A02BC02 141 pantoprazole Pantoprazol PharmaS tbl. 28x20 mg 1,63 45,72 1,47 41,15
A02BC02 146 pantoprazole Pantoprazol Genera tbl. 28x20 mg 1,47 41,15 1,47 41,15






D) Potential savings with the new ordinances 
 
Calculations undertaken before the new ordinances were implemented regarding ERP believed the 
new ordinances, with changes in the order of the reference price countries (Table 2), would lower 
prices by an average of 8 to 10%. This is less than the potential savings of 10% to 35% under the old 
ordinance with prices lowered by 65% to 90% of the ACP (Table 2). However, the documented price 
reductions under the old ordinance were seen as large and potentially restrictive to new medicines. 
The changes in the new ordinance to 100% of comparative prices (Table 1) are seen as more 
acceptable to key stakeholder groups especially if Croatia is a reference priced country.  
 
The overall projections for potential savings are based on changes in the ERP system with the new 
ordinances, incorporating all medicines in the basic and supplementary list including generics and 
biosimilars, factors concerned with wholesale and retail prices as well as changes in the order of the 
reference countries (Tables 1 and 2) described in the Methodology section. This does not apply to 
new medicines where none has existed before to treat a given disease as these costs will be in 
addition. There are separate projections based on changes in the IRP system, including medicines 
placed in the 54 reference groups. As mentioned, IRP in Croatia is determined at ATC level III to V. 
Consequently, this was the principal model used to calculate potential savings for the new ordinance 
in the current reference groups. Potential savings were compared to just concentrating at ATC Level 
V when determining potential internal reference prices for comparative purposes. 
 
Based on 2011 consumption and projected expenditure in 2012 outlined in the Methodology section, 
projections showed possible savings of 318.4 million kunas for CHIF for the 54 reference groups 
(Table 5). This represents savings of 9.64% for reimbursed drugs based on projected 2012 
consumption figures. Setting the reference price of medicines (IRP) at the ATC level V rather than III 
to V yielded potential savings of 254.45 million kunas, i.e. 7.7%  of total CHIF expenditure on 
ambulatory care medicines in 2012 (34). Table 5 shows projected savings for each of the 54 
reference groups (ATC III to V). 2,028 packages of different medicines were included in the 54 
reference price groups in 2012, forming the basis of the calculated savings. 
 
Projected savings from the new ordinances for CHIF for medicines on the current lists will grow as 
more generic medicines are launched as well as more biosimilars for the same medicine and for new 




Table 5 ± Projected savings for the 54 reference groups 
 
Referencing groups ATC level III-V
1 A02BA H2 - receptor agoinsts 6,030,470.16
2 A02BC proton pump inhibitors 43,641,912.50
3 A06 drugs for constipation 164,915.66
4 A07 aminosalicylic acid and similar agents 17,753.94
5 A10A inuslins 2,561,124.80
6 A10B other drugs used in diabetes 2,155,857.16
7 B01 antithrombotic agents 8,503,059.07
8 B03 antianemic preparations 0.00
9 C01B antiarrhitmics 204,514.74
10 C01D vasodilatators 1,965,105.12
11 C02 antihypertensives 1,584,140.45
12 C03 diuretics 1,371,952.28
13 C07 beta blocking agents 3,092,925.10
14 C08 calcium channel blockers 3,602,841.53
15 C09A ACE - inhibitors 26,686,891.22
16 C09B ACE - inhibitors, combinations 29,414,074.57
17 C09C angiotensin II antagonists 3,019,977.35
18 C09D angiotensin II antagonists, combinations 2,183,246.03
19 C10 lipid modifynig agents 69,885,918.43
20 D01 (A01) stomatological preparations, antimycotics 1,071,092.01
21 D06 antibiotics and chemoterapeutics - dermatological use 52,965.15
22 D07 corticosteroids, dermatological preprations 1,819,225.95
23 G01 gynecological antiinfectives and antiseptics 243,679.98
24 G03 sex hormones and other 0.00
25 G04B urologicals 199,072.36
26 G04C drugs used in benign prostatic hypertrophy 6,640,684.37
27 H02 corticosteroids for systemic use 0.00
28 H03 thyroid therapy 214,972.65
29 J01C beta-lactam antibacterials, penicillins 12,289,463.46
30 J01D other beta-lactam antibacterials 4,030,062.84
31 J01E sulfonamides and trimethoprim 0.00
32 J01F macrolides 12,324,857.29
33 J01M quinolone antibacterials 564,253.59
34 J02 antimycotics for system use 240,049.71
35 L02B hormone antagonists 14,554,448.15
36 L04A immunosupressants 950,995.74
37 M01 antirheumatics 1,179.48
38 M05 drugs for treatment of bone diseases 646,884.70
39 N02A analgesics 8,171,763.49
40 N02C antimigraine preparations 17,267.31
41 N03 antiepileptics 1,661,959.86
42 N04 anti-parkinsonian drugs 0.00
43 N05A antipsyhotics 22,874,399.11
44 N05B anxiolytics 1,039,620.12
45 N05C hypnotics and sedatives 1,064,121.74
46 N06 antidepresives 14,413,394.91
47 N07 other nervous system drugs 1,952,430.72
48 R01 nasal preparations 0.00
49 R03A adrenergics, inhalants 8,549.64
50 R05 cough preparations 963,762.10
51 R06 antihistamines for systemic use 1,253,949.20
52 S01B antiinflammatory agents 113,711.25
53 S01E antiglaucoma preparations and other 334,310.95
54 V06 nutrients 2,598,341.64
Total: 318,398,149.58







Different European countries have used different models and approaches for determining the price of 
new and established medicines including generics. This includes both internal and external reference 
pricing, with differences in external reference pricing in terms of the number of countries chosen, their 
sequence, methods for establishing reference prices as well as time frames for their review (10, 17, 
39-42).  
 
This paper demonstrates that changes in the reference pricing system can lead to considerable 
differences in overall reimbursed expenditure. In addition, European countries with smaller 
populations, i.e.  4.27 million inhabitants in 2012 year, can be active with introducing a variety of 
measures to help control pharmaceutical expenditure whilst increasing access to new medicines. This 
includes changes in reference price systems and the pricing of medicines losing their patent.  
 
The calculated savings from the changes in the ERP system, including the order of chosen countries 
(Table 2), were estimated at an average of 8 to 10%. The calculated savings from the changes in the 
IRP systems were estimated at 318.4 million kunas among the 54 reference groups (Table 5), i.e. 
9.64% of reimbursed drug expenditure in 2012, reduced to 254.45 million kunas, i.e. 7.7% of total 
CHIF expenditure, if the IRP is just based on ATC Level V (34). As a result, endorsing CHIF's 
decision to use ATC Level III to V for internal reference pricing and the development of the new 
ordinance. This provides guidance to other countries using reference pricing particularly once 
generics become available in a class to help control pharmaceutical expenditure. This difference is 
also a potential way to address concerns regarding the lack of transparency in the prices of reference 
priced countries. 
 
We are aware of a number of controversies surrounding external reference pricing. This includes the 
fact that prices of medicines in countries may not reflect actual prices (10, 12, 43, 44). In addition, 
pharmaceutical companies may preferentially launch their new medicines initially in traditionally 
higher price countries thereby potentially increasing the prices in the remaining countries that directly 
or indirectly reference them (12). Thirdly, price reductions in one reference country may not 
automatically apply to other reference countries unless there are mechanisms to rapidly assess this. 
As a result, reduce potential savings (12). Finally, pharmaceutical companies could potentially 
withhold launching their new medicines in lower priced countries as this may adversely affect overall 
profitability. However, the initial reforms in Croatia resulted in 85 new medicines being added to the 
reimbursement list between 2009 and 2011 coupled with a deficit reduction (14, 30). This was up from 
47 new medicines between July 2009 and 2010, with 13 new medicines added to the list of expensive 
hospital products (15). In addition, we believe the changes in the new ordinance (Tables 1 and 2) 
should be beneficial to all key stakeholder groups with prices of both patented and multiple sourced 
medicines remaining at 100% as opposed to 65% to 90% of ACP. Whilst potentially resulting in lower 
savings for CHIF, this should enhance the attractiveness of this ordinance to key stakeholder groups, 
addressing some of the concerns that companies will not launch their new medicines in lower priced 
countries. The new ordinances with no automatic price reductions for new medicines (Tables 1 and 2) 
should also be beneficial to pharmaceutical companies enhancing their desire to launch new 
medicines in Croatia. As mentioned, lower prices for established medicines including generics and 
biosimilars should be beneficial to patients, reducing their co-payment levels as well as creating 
headroom for new medicines. 
 
We are also aware that there are controversies surrounding the selection of countries for external 
reference pricing, although most countries appear to reference those of similar income levels (10). In 
this respect, we believe the change in the order of countries brings Croatia in line with other European 
countries, i.e. higher income countries tend to include higher income countries in their basket whereas 
lower income countries tend to reference lower income countries (10). The use of 5 countries is also 
similar to other European countries, who tend to have less than 10 countries in their reference 
baskets (10). Wholesale prices should also be more uniform that pharmacy prices as there can be 
considerable differences in pharmacy remuneration and taxes between countries (10). As a result, 
endorsing the new approach (Tables 1 and 2). 
 
We are aware that some European countries review their prices more regularly than Croatia to 
improve transparency (9, 11). Applying this approach in Croatia could potentially lead to greater 
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savings than those achieved by the recent changes in the ordinances (Tables 1, 2, and 5). However, 
instigating a greater number of internal and external pricing reviews would need new procedures and 
workflows, a consensus in how this can be achieved. In addition,  an assessment of the implications 
for all key stakeholder groups including wholesalers, pharmacies, marketing authorisation holders and 
others. Alongside this, the necessity to have transparent information systems that will continually 
monitor prices of medicines in the external reference price countries as well as possible changes to 
legal entities. The increased costs would impact on the extent of any potential savings. Having said 
this, this possibility should not be discarded if further savings are needed in Croatia in the future. 
 
Finally, we are aware that the new ordinance has not discussed potential initiatives to improve the 
quality of prescribing apart from prescribing restrictions for certain medicines, e.g. angiotensin 
receptor blockers and curbing pharmaceutical company marketing activities (14, 18). In addition, the 
instigation of ePrescribing from January 2011 making medicines more accessible without patients 
visiting their physician. Possible measures could include initiatives to reduce adverse drug reactions 
(ADRs) and drug interactions including decision support systems in conjunction with eprescribing (45, 
46). Treating ADRs can be costly to health authorities as well as adversely affecting the health of 
patients. Published studies have shown that ADRs add to the costs of healthcare through increasing 
hospital admissions and other costs (47-49). For example, the average treatment costs in Germany 
were HVWLPDWHGDWDSSUR[LPDWHO\¼/ ADRHTXDWLQJWR¼PLOOLRQSHU\HDU(50), with the cost of 
drug-related morbidity and mortality exceeding US$177.4bn in the US in 2000 (51). This is despite the 
proclaimed goal of the authorities in Croatia to introduce and implement for instance external 
evaluation of the quality of health care institutions (31).  
 
The strength of these findings are based on the fact that the ordinances and findings are based on 
CHIF data, which is regularly audited. The weakness is the fact that these are projections. We will 
continue to monitor the situation and provide feedback to CHIF if further ordinances are needed. 
 
Potential ways forward in addition to potential price cuts to help Croatia stay within agreed 
pharmaceutical expenditure (52)  could include greater education of patients concerning the 
medicines they receive. As a result, reduce unnecessary requests for medicines as well as improve 
compliance, which is a concern in patients with chronic asymptomatic diseases (53, 54). Other 
potential initiatives could include the instigation of active regional drugs and therapeutic committees 
deciding which medicines to use to treat common diseases in ambulatory care, building on the current 
reimbursement list. This is because there are concerns with the evidence base of the medicines 
included in the current reimbursement list (55), as well as typically physicians only knowing a 
relatively limited number of medicines well. This was the philosophy of the Stockholm Metropolitan 
Healthcare Region in Sweden where there has been a tradition of DGYRFDWLQJ³HDFKUHFRPPHQGHG
PHGLFLQHVKRXOGEHRIKLJKYDOXHWRWKHSDWLHQW´ (56, 57). Since 2000, approximately 200 medicines 
have been selected for common diseases in ambulatory care (56). Respected specialists, working 
jointly with clinical pharmacologists, pharmacists and general practitioners in over 20 expert groups, 
suggest which medicines should be selected and included in the µ:LVHOist¶(56, 58), which is then 
widely communicated and disseminated throughout Stockholm (56, 57).  Physician adherence to the 
YROXQWDU\µ:LVH/LVW¶KDVLQFUHDVHGGXULng the past 10 years, now reaching 87% of all prescriptions, 
enhanced by physician trust in the µ:LVHList¶ZLth its robust methodologies (56, 58)7KHµ:LVH/LVW¶LV
now being translated into other languages to provide a stimulus to introducing such initiatives (59). 
 
Concurrent with this, there is also likely to be increasing scrutiny over the value of new medicines 
where there is currently no existing treatment in Croatia for comparative purposes. This recognises 
the appreciable number of new medicines in development, especially new biological medicines which 
are currently often priced at between US$100,000 - US$400,000 (Euro74,000 ± 296,000) per patient 




In conclusion, we have described the similarities and changes to the ordinance in Croatia for both 
new and established medicines including generics and biosimilars and the implications. In addition, 
the implications for savings through re-ordering the list of reference priced countries (ERP) as well as 
the subsequent implications for savings with IRP at ATC Level III to V versus  ATC Level V alone. We 
hope the findings will be of interest to other European countries. In addition, demonstrate that 
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European countries with smaller populations can be active with introducing a variety of measures 
when needed. This is in the best interests of all key stakeholder groups.  
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Glossary 
ACP ± average comparable price 
ADR - adverse drug reactions 
ATC - The Anatomical Therapeutic Chemical classification system 
CHIF ± Croatian Health Insurance Fund 
DDD - defined daily dose 
ERP ± external reference pricing 
IRP ± internal reference pricing 
PPI ± proton pump inhibitors 
RP ± retail price 
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